問卷

TPIDB > Principal Investigator

Principal Investigator



更新時間:2023-09-19

李政學
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

11Cases

2017-06-15 - 2025-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated4Sites

2021-12-30 - 2027-04-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-10-26 - 2028-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting3Sites

Recruiting5Sites

2021-01-01 - 2029-10-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2019-01-01 - 2027-05-27

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2020-06-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2020-08-01 - 2023-08-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
19Sites

Not yet recruiting8Sites

Recruiting1Sites

Terminated10Sites

2022-08-01 - 2026-08-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-08-01 - 2028-01-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting4Sites

Recruiting4Sites

2017-08-01 - 2020-12-31

Phase III

HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer
  • Condition/Disease

    Advanced Prostate Cancer

  • Test Drug

    Relugolix 120 mg

Participate Sites
5Sites

Terminated4Sites

1 2